Johnson & Johnson banner

Johnson & Johnson
DUS:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
DUS:JNJ
Watchlist
Price: 192.26 EUR -2.46% Market Closed
Market Cap: €463.3B

Revenue Breakdown

Breakdown by Geography
Johnson & Johnson

Total Revenue: 94.2B USD
100%
United States Plans: 50.3B USD
53.4%
Non-Us: 38.5B USD
40.9%

Breakdown by Segments
Johnson & Johnson

Total Revenue: 94.2B USD
100%
Innovative Medicine: 57B USD
60.5%
Medtech: 31.9B USD
33.8%
Darzalex: 11.7B USD
12.4%
Stelara: 10.4B USD
11%
General: 5.4B USD
5.7%
Electrophysiology: 5.3B USD
5.6%
Advanced: 4.5B USD
4.8%
Invega Sustenna/Xeplion/Trinza/Trevicta: 4.2B USD
4.5%
Contact Lenses/Other: 3.7B USD
4%
Tremfya: 3.7B USD
3.9%
Trauma: 3B USD
3.2%
Imbruvica: 3B USD
3.2%
Erleada: 3B USD
3.2%
Spine,Sports & Other: 2.9B USD
3.1%
Xarelto: 2.4B USD
2.5%
Simponi/Simponi Aria: 2.2B USD
2.3%
Opsumit: 2.2B USD
2.3%
Uptravi: 1.8B USD
1.9%
Prezista/Prezcobix/Rezolsta/Symtuza: 1.7B USD
1.8%
Hips: 1.6B USD
1.7%
Remicade: 1.6B USD
1.7%
Knees: 1.5B USD
1.6%
Abiomed: 1.5B USD
1.6%
Surgical: 1.4B USD
1.5%
Edurant/Rilpivirine: 1.3B USD
1.4%
Other: 1.2B USD
1.3%
Other Neuroscience: 1.2B USD
1.2%
Spravato: 1.1B USD
1.1%
Carvykti: 963m USD
1%
Other Oncology: 931m USD
1%
Concerta/Methylphenidate: 641m USD
0.7%
Zytiga/Abiraterone Acetate: 631m USD
0.7%
Shockwave Medical, Inc: 564m USD
0.6%
Tecvayli: 549m USD
0.6%
Other Cardiovascular: 380m USD
0.4%
Other Pulmonary Hypertension: 281m USD
0.3%
Other Infectious Diseases: 214m USD
0.2%
Covid-19: 198m USD
0.2%
Other Immunology: 3m USD
0%
Show More
Show Less
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett